EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies

Bongiwe Ndlovu, Kamini Gounder, Nelisiwe Zikhali, Lanish Singh, Ntokozo Ntshangase, Nombali Gumede, Jane Millar, Rebecca T van Dorsten, Nicholas E Grayson, David Bonsall, Sandra E Chaudron, Jennifer Mabuka und 5 weitere

PLOS Pathogens · 23.06.2025 · 21 (6) · e1013245

DOI: 10.1371/journal.ppat.1013245 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 23.06.2025. Verfasst von Bongiwe Ndlovu und 16 weiteren Autor:innen. Beteiligte Einrichtung: HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Antibodies, Antibodies, Neutralizing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Gates Foundation, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Broadly neutralizing antibodies (bnAbs), passively administered or elicited through vaccination, are a promising strategy for novel HIV prevention, treatment or inducing ART-free remission. However, HIV diversity and evolution are a barrier to the efficacy of bnAbs and there is therefore an urgent need for continuous virus surveillance to identify bnAbs with optimal neutralization breadth and potency against transmitted/founder (TF) viruses, especially in high-burden regions. We determined the neutralization sensitivity of TF viruses isolated within seven days after first detection of heterosexually acquired infection from young women 18–23 years old (n = 39) and within 1 month after birth from in-utero infected infants (n = 21) from FRESH and Baby Cure cohorts respectively, in KwaZulu-Natal, South Africa, where HIV-1 subtype C predominates. Neutralization sensitivities of 47 viruses from FRESH and 21 viruses from Baby Cure were assessed against nine bnAbs targeting different regions on the HIV-1 Env trimer. HIV-1 env sequences within and between bnAb epitopes were compared with database. The bnAbs VRC07–523LS, CAP256-VRC26.25, PGDM1400, 10E8 and PGT151 displayed higher neutralization breadth and potency than other bnAbs against FRESH TF viruses (>70% coverage, starting concentration of 10 μg/ml). Furthermore, VRC07–523LS showed higher neutralization breadth and potency than other bnAbs against Baby Cure TF viruses (p = 0.02). Interestingly, CAP256-VRC26.25 and PGT151 had lower neutralization coverage against infant TF viruses (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHIV AntibodiesAntibodies, NeutralizingAntibodies, MonoclonalHumansFemaleInfantYoung AdultAdolescentNeutralization TestsAdultSouth Africaenv Gene Products, Human Immunodeficiency VirusEpitopesBroadly Neutralizing AntibodiesInfant, NewbornInfectious Disease Transmission, Vertical

Substanzen

HIV AntibodiesAntibodies, NeutralizingAntibodies, Monoclonalenv Gene Products, Human Immunodeficiency VirusEpitopesBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.
  • Africa Health Research Institute, Durban, South Africa.
  • Division of Infection and Immunity, University College London, London, United Kingdom.
  • Department of Paediatrics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Centre for HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Wellcome Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

ORCID-Profile: Thumbi Ndung'u

Förderung

  • Wellcome Trust
  • Gates Foundation
  • NIAID NIH HHS
  • Bill and Melinda Gates Foundation
  • European and Developing Countries Clinical Trials Partnership
  • National Research Foundation Thuthuka Program
  • Gilead Sciences
  • International AIDS Vaccine Initiative

Zitieren

APA

Ndlovu, B., Gounder, K., Zikhali, N., Singh, L., Ntshangase, N., Gumede, N., Millar, J., van Dorsten, R. T., Grayson, N. E., Bonsall, D., Chaudron, S. E., Mabuka, J., Dong, K. L., Walker, B. D., Moore, P. L., Goulder, P. J. R., & Ndung'u, T. (2025). Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies. PLOS Pathogens, 21(6), e1013245. https://doi.org/10.1371/journal.ppat.1013245

Vancouver

Ndlovu B, Gounder K, Zikhali N, Singh L, Ntshangase N, Gumede N, et al. Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies. PLOS Pathogens. 2025;21(6):e1013245. doi:10.1371/journal.ppat.1013245

BibTeX
@article{Ndlovu2025,
  author = {Ndlovu, Bongiwe and Gounder, Kamini and Zikhali, Nelisiwe and Singh, Lanish and Ntshangase, Ntokozo and Gumede, Nombali and Millar, Jane and van Dorsten, Rebecca T and Grayson, Nicholas E and Bonsall, David and Chaudron, Sandra E and Mabuka, Jennifer and Dong, Krista L and Walker, Bruce D and Moore, Penny L and Goulder, Philip J R and Ndung'u, Thumbi},
  title = {Distinct neutralization sensitivity between adult and infant transmitted/founder HIV-1 subtype C viruses to broadly neutralizing monoclonal antibodies},
  journal = {PLOS Pathogens},
  year = {2025},
  volume = {21},
  number = {6},
  pages = {e1013245},
  doi = {10.1371/journal.ppat.1013245}
}
Kostenlos starten →